Sullivan Eddie Joe

SEC source: 0001193125-26-039577 · ownership.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000,000

Underlying: Common Stock · 3,000,000 shares

Expires 2036-02-03

F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0000950170-25-112043 · ownership.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000,000

Underlying: Common Stock · 3,000,000 shares

Expires 2035-08-26

F1 · shares: Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").

F2 · shares: The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.

F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0000950170-24-084292 · ownership.xml · derivative · entry 2

Sullivan Eddie Joe · CIK 0001889712 · Director · PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,447

Underlying: Common Stock · 4,447 shares

Expires 2034-07-15

F2 · security: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028.

F3 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest 25% on July 15, 2025, and in equal monthly installments thereafter over a three-year period ending July 15, 2028.

SEC source: 0000950170-24-084292 · ownership.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,528

Underlying: Common Stock · 46,528 shares

Expires 2034-07-15

F1 · security: Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option are fully vested.

F3 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F1 · derivative.exercise_date: Represents a one-time grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option are fully vested.

SEC source: 0000950170-24-019441 · ownership.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · PRESIDENT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2034-02-21

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0000950170-23-068922 · ownership.xml · nonDerivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,232,304

F1 · kind: Represents 1,740 shares of the Issuer's common stock, par value $0.0001 per share, acquired by the reporting person in an open market transaction.

SEC source: 0001437749-23-006911 · rdgdoc.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,000

Underlying: Common Stock · 525,000 shares

Expires 2033-03-14

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-050105 · doc4.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2032-09-13

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

SEC source: 0001209191-22-049168 · doc4.xml · nonDerivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · CHIEF EXECUTIVE OFFICER · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,230,564

SEC source: 0000899243-22-011667 · doc4.xml · derivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,218

Underlying: Common Stock · 21,218 shares

Expires 2033-03-16

F1 · shares: Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 8

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,374

Underlying: Common Stock · 197,374 shares

Expires not disclosed

F7 · derivative.exercise_price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F7 · price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F7 · derivative.exercise_date: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F3 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 7

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,264

Underlying: Common Stock · 23,264 shares

Expires 2030-04-27

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 6

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,850

Underlying: Common Stock · 162,850 shares

Expires 2024-12-12

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 5

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,850

Underlying: Common Stock · 162,850 shares

Expires 2024-12-12

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 4

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,585

Underlying: Common Stock · 139,585 shares

Expires 2024-08-05

F5 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · price: The option is fully vested.

F5 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F6 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026387 · ownership.xml · derivative · entry 3

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,106,361

Underlying: Common Stock · 2,106,361 shares

Expires not disclosed

F3 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F4 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F3 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026387 · ownership.xml · nonDerivative · entry 1

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,213,764

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

SEC source: 0001493152-21-026387 · ownership.xml · nonDerivative · entry 2

Sullivan Eddie Joe · CIK 0001889712 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,800

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.